New Covid vaccines, for example, will become available in the U.S. this fall. Pfizer

 New Covid vaccines, for example, will become available in the U.S. this fall. Pfizer

Moderna and Novavax have all updated single-strain shots, though public health officials expect uptake to be low. In fact, CDC data indicates that just 17% of the U.S. population has gotten the bivalent boosters approved last September.

In June, the FDA advised drugmakers to update the Covid booster shots to target XBB.1.5, which is currently the predominant strain in the United States. The goal was to give drugmakers enough time to make the boosters available in the fall, and all the major players seem to be on target thus far.

Despite the new vaccines coming, the low demand was a culprit in Pfizer’s earnings miss. The company’s revenue was just $12.7 billion for the second quarter, which fell short of the $13.4 billion analysts predicted. Meanwhile, Moderna’s Q2 report revealed $344 million in revenue, which was sharply down from last year but still beat estimates.

Comments

Popular posts from this blog

News, Biogen has announced plans to buy Reata Pharmaceuticals for $7.3 billion.